Taysha Gene Therapies Inc

TSHA

Company Profile

  • Business description

    Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

  • Contact

    3000 Pegasus Park Drive
    Suite 1430
    DallasTX75247
    USA

    T: +1 214 612-0000

    https://www.tayshagtx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    99

Stocks News & Analysis

stocks

ASX growth share with attractive dividend

Worries about AI overblown.
stocks

Higher fair value for undervalued wide moat share

Investors are overly concerned with upcoming capital expenditures.
stocks

Fears of deteriorating loan quality sends bank share plummeting

We maintain our fair value estimate despite unfavourable economic conditions.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,026.9046.300.52%
CAC 408,381.763.11-0.04%
DAX 4024,708.2537.030.15%
Dow JONES (US)51,876.1144.51-0.09%
FTSE 10010,507.130.89-0.01%
HKSE23,026.68354.821.57%
NASDAQ25,297.6260.99-0.24%
Nikkei 22569,468.11107.230.15%
NZX 50 Index13,545.5650.320.37%
S&P 5007,354.020.000.00%
S&P/ASX 2008,823.4046.500.53%
SSE Composite Index4,073.9046.641.16%

Market Movers